Halozyme Therapeutics (HALO) Invested Capital (2013 - 2026)

Halozyme Therapeutics (HALO) has 12 years of Invested Capital data on file, last reported at $208.7 million in Q1 2026.

• On a quarterly basis, Invested Capital changed N/A year-over-year to $208.7 million in Q1 2026; TTM through Mar 2026 was $919.4 million, a N/A change from a year earlier, with the FY2022 full-year figure at $13.3 million, down 85.09% from the prior year.
• Invested Capital for Q1 2026 stood at $208.7 million, down from $710.7 million in the prior quarter.
• Over the last five years, Invested Capital for HALO reached as high as $710.7 million in Q3 2025 and fell as low as $13.3 million in Q3 2022.
• Historically, Invested Capital has averaged $189.1 million across 3 years, with a median of $94.3 million in 2022.
• On a YoY basis, Invested Capital climbed as much as 11.08% in 2022 and fell as far as 85.09% in 2022.
• Year by year, Invested Capital stood at $13.3 million in 2022, then jumped by 5229.87% to $710.7 million in 2025, then tumbled by 70.63% to $208.7 million in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $208.7 million in Q1 2026, $710.7 million in Q3 2025, and $13.3 million in Q4 2022.